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Cardiovascular sequelae of the sleep apnoea syndrome: sex, stress and 
therapeutic strategies 
 
In this issue of Acta Physiologica, Ribon-Demars et al.
1
 report that exogenous oestradiol 
administration mitigates vascular oxidative stress and elevated blood pressure in an ovariectomized 
rat model of sleep-disordered breathing. Sleep apnoea is a major public health issue. If untreated, it 
leads to premature death. Obstructive sleep apnoea, the most prevalent form of sleep-disordered 
breathing, is very common, but remains under-diagnosed. The underlying causes of disordered 
breathing during sleep
2
 relate to aberrant airway anatomy as a primary driver, and additional 
physiological traits such as inadequate function and control of the upper airway muscles; increased 
likelihood of awakening during airway obstruction (low arousal threshold); and respiratory control 
instability (increased loop gain). Narrowing or occlusion of the upper airway arises from sleep-related 
reductions in the motor drive to the pharyngeal muscles, which are pivotal in the control of upper 
airway calibre and collapsibility. This natural state-dependent reduction in cranial nerve activity is 
problematic for a majority of sleep apnoea patients with at-risk i.e. narrow/collapsible airways. The 
Wisconsin Sleep Cohort Study
3
 established prevalence estimates of moderate-to-severe sleep-
disordered breathing at 10% (30-49-year-old men); 17% (50-70-year-old men); 3% (30-49-year-old 
women); and 9% (50-70 year-old women). Rather worryingly, the estimated prevalence rates have 
increased substantially over the last two decades, most likely a reflection of the growing obesity 
epidemic. Strikingly, the prevalence of sleep apnoea is much greater in men compared with women. 
However, progression through menopause is associated with greater severity of sleep-disordered 
breathing, independent of aging and changes in body habitus,
4
 such that prevalence estimates are 
generally equivalent between post-menopausal women and age-matched males, revealing the critical 
influence of sex hormones in the propensity for the development of sleep apnoea.  
The disruptive and harmful sequelae of the sleep apnoea syndrome can include excessive 
daytime sleepiness, neurocognitive impairments, metabolic dysregulation, and overt cardiovascular 
morbidity. Evidence points to a strong link between sleep apnoea and cardiac dysrhythmia, coronary 
artery disease, heart failure, vascular endothelial dysfunction, increased risk of stroke and vascular 
dementia, and most compellingly, hypertension
5
, albeit with some reservations. Repeated occlusions 
of the upper airways evoke pressor responses and nocturnal hypertension. Strikingly, in many persons 
with sleep apnoea blood pressure is elevated during the daytime associated with persistent diurnal 
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associated with periodic occlusions of the upper airways during sleep in apnoeic patients result in 
arterial blood gas derangements, seen clinically as episodic arterial blood deoxygenation followed by 
reoxygenation resulting from restoration of airflow.  Thus, long-term exposure to chronic intermittent 
hypoxia (CIH) is a cardinal feature of the sleep apnoea syndrome, and is sufficient to cause symaptho-
excitation and elevated blood pressure in human subjects
 
and various animal models. 
 
In the comprehensive and carefully-conducted studies by Ribon-Demars et al.,
1
 adult female 
rats were exposed to normoxia or CIH, modelling mild sleep apnoea; subsets of rats within these two 
groups underwent sham surgery or were ovariectomized with subsequent chronic vehicle or chronic 
17β oestradiol administration. Exposures to IH lasted 7 or 35 days allowing the comparison of 
responses in the period of the development of cardiovascular morbidity (days) and its relatively 
prolonged maintenance (weeks); outcomes which may depend on different driving mechanisms. 
Blood pressure, heart rate and plasma endothelin-1 levels (a potent vasoconstrictor) were determined, 
accompanied by assessments of thoracic aorta reactivity and oxidant status. The study design allowed 
for the consideration of important questions: What are the cardiovascular consequences of exposure to 
CIH over varying time domains in the presence and absence of ovarian steroid hormones? Does 17β 
oestradiol treatment ameliorate hypertension and vascular oxidative stress and dysfunction in 
ovariectomized rats during normoxia and CIH? This broad vista is a notable strength of the study---an 
important area of investigation in the context of cardiovascular risk in perimenopausal women with 
and without sleep-disordered breathing. 
Exposure to IH raised blood pressure after 7 and 35 days in sham and ovariectomized rats; 
tachycardia and increased plasma endothelin-1 levels were evident during early hypoxic stress, but 
values were equivalent to respective control levels after several weeks’ exposure. 17β oestradiol 
treatment ameliorated hypertension in IH exposed rats, but blood pressure remained elevated, a result 
of ovariectomy per se, which was not amenable to 17β oestradiol treatment. In rats exposed to 7 days 
of IH, replacement hormone treatment restored heart rate and peripheral endothelin-1 levels. In 
thoracic aorta samples, the activity of reactive oxygen species generating cytosolic oxidases (NADPH 
oxidase and xanthine oxidase) was elevated in ovariectomized rats after 7 days, both in normoxia and 
IH, with attendant increased protein oxidation indicative of oxidative stress. Interestingly, 17β 
oestradiol treatment reversed aortic oxidative stress in ovariectomized rats, but by mechanisms that 
differed in normoxic (normal pro-oxidant enzyme activities) and IH exposed animals (abrogated 
increased glutathione peroxidase activity together with increased catalase but not superoxide 
dismutase activity). Surprisingly, all measures of oxidant status were equivalent between all groups at 
35 days. Contractile responses of aortic rings to phenylephrine were blunted in short-term IH exposed 
sham but not ovariectomized rats; 17β oestradiol treatment led to potentiated contractile responses to 
alpha-adrenergic stimulation with phenylephrine. Assessment of vascular relaxation revealed slightly 
blunted   responses to acetylcholine (endothelium-dependent), but not sodium nitroprusside 
(endothelium-independent), in ovariectomized rats exposed to short-term IH, which was amenable to 
17β oestradiol treatment. Vascular reactivity was similar in all groups at 35 days, mirroring the 
consistency in aortic oxidant:antioxidant status parameters at this time point. 
The study by Ribon-Demars et al.
1
 illustrates that modest IH evokes hypertension in female 
rats, with no sex advantage or protection as is commonly observed in other forms of experimentally-
induced hypertension. 17β oestradiol treatment ameliorates IH-induced hypertension, which most 
likely relates to recovery of IH-induced enhanced chemoreflex activation of sympathetic outflow as 
shown previously by this group
6
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unresponsive to 17β oestradiol treatment suggesting an alternative underlying mechanism of action. 
Of interest, short-term IH evoked only modest vascular oxidative stress and aortic dysfunction, which 
was fully resolved following long-term IH exposure, which differs from observations of aortic and 
arteriolar stress and dysfunction in male rats, revealing sex differences that are independent of the 
prevailing hormonal status. It appears that female vascular tissue is relatively tolerant of IH, which 
may relate to oestrogen-oestrogen receptor axis signalling and intrinsic resilience in female peripheral 
vascular tissues, similar to observations in skeletal muscle
7
. Nevertheless, ovariectomy provokes 
oxidative stress in the acute phase in normoxia revealing the antioxidant properties of ovarian 
hormones in vascular tissues. Altogether, fascinating stuff but not for the faint-hearted! 
The authors acknowledge several limitations of the study, principally the biochemical and 
physiological assessment of a major conduit artery and not skeletal muscle resistance arterioles that 
predominantly contribute to arterial blood pressure regulation. Indeed, the observations of Ribon-
Demars et al.
1 
may have greater relevance to sleep-disordered breathing in the perimenopausal period 
and risk for aortic disease and/or aortic stiffness. Further work is required to confirm or otherwise in 
various vascular beds whether there are differences in female resistance arteriole reactivity following 
exposures to IH in the presence and absence of ovarian hormones compared with males. The potential 
influence of age and other morbid burdens is worthy of pursuit. Whilst we eagerly await the outcomes 
of those and other potential avenues of exploration, the elegant work of Ribon-Demars et al.
1
 should 
provoke further debate of the potential therapeutic benefit of hormone replacement therapy (or 
perhaps other antioxidant strategies) in mitigating cardiovascular risk in menopausal women.    
 
CONFLICT OF INTEREST 
None. 
 
Ken D. O’Halloran 
Department of Physiology, School of Medicine, College of Medicine & Health, University College 




1. Ribon-Demars A, Pialoux V, Boreau A, et al. Protective roles of estradiol against vascular 
oxidative stress in ovariectomized female rats exposed to normoxia or intermittent hypoxia. Acta 
Physiol (Oxf.). 2018; DOI: 10.1111/apha.13159. 
2. Eckert DJ. Phenotypic approaches to obstructive sleep apnoea - New pathways for targeted therapy. 
Sleep Med Rev. 2018;37:45-59. 
 
3. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-











This article is protected by copyright. All rights reserved. 
4. Mirer AG, Young T, Palta M, Benca RM, Rasmuson A, Peppard PE. Sleep-disordered breathing 
and the menopausal transition among participants in the Sleep in Midlife Women Study. 
Menopause. 2017;24:157-162.  
 
5. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep apnea: Types, mechanisms, and clinical 
cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841-858. 
 
6. Laouafa S, Ribon-Demars A, Marcouiller F, et al. Estradiol protects against cardiorespiratory 
dysfunctions and oxidative stress in intermittent hypoxia. Sleep. 2017;40(8).  
 
7. O'Halloran KD, Lewis P, McDonald F. Sex, stress and sleep apnoea: Decreased susceptibility to 
upper airway muscle dysfunction following intermittent hypoxia in females. Respir Physiol 
Neurobiol. 2017;245:76-82. 
 
 
